Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIB | P23284 | 4/20 | 0.82 |
| ▸ | PPID | Q08752 | 14/20 | 0.75 |
| ▸ | PPIG | Q13427 | 6/20 | 0.75 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | FAP | Q12884 | 2/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2034766 | 0.90 | PPIB (1.00) | PPIBPPIDPPIGHSP90AA1HSP90AB1 | |
| SCHEMBL2039766 | 0.85 | PPID (1.00) | PPIBPPIDPPIG | |
| SCHEMBL2035376 | 0.83 | PPID (0.94) | PPIBPPIDPPIG | |
| SCHEMBL19882167 | 0.82 | PPID (0.77) | PPIBPPIDPPIGHSP90AA1HSP90AB1 | |
| SCHEMBL2043239 | 0.79 | PPID (0.83) | PPIBPPIDPPIG | |
| SCHEMBL19882148 | 0.78 | PPID (0.68) | PPIBPPIDPPIGMEN1KMT2A | |
| SCHEMBL2040168 | 0.74 | PPID (0.79) | PPIBPPIDPPIG | |
| SCHEMBL2042889 | 0.74 | PPID (0.77) | PPIBPPIDPPIG | |
| SCHEMBL19882156 | 0.74 | PPID (0.64) | PPIBPPIDPPIG | |
| SCHEMBL28056208 | 0.73 | PPID (0.81) | PPIBPPIDPPIG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018044-A1 | NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOF | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018044-A1 | NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOF | FKBP3, FKBP4, FKBP5 | PPIB 51/4885PPID 73/4885PPIG 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.